Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Fabric.AI, Inc.FABC · Entity 7732 | Chief Financial Officer | June 18, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Fabric.AI, Inc.
Report date June 18, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $3.70 · Expires 2036-06-18 | Direct | 50,000 |
Reported balance
After 2026-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 50,000 · Balance 50,000 F1: The stock options vest as follows: (i) 25% vested upon the date of grant; (ii) 25% will vest on June 30, 2026, (iii) 25% will vest on September 30, 2026, and (iv) 25% will vest on December 31, 2026, provided that the Reporting Person remains employed by or providing services to the Issuer on the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options vest as follows: (i) 25% vested upon the date of grant; (ii) 25% will vest on June 30, 2026, (iii) 25% will vest on September 30, 2026, and (iv) 25% will vest on December 31, 2026, provided that the Reporting Person remains employed by or providing services to the Issuer on the applicable vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Adhera Therapeutics, Inc.
Report date May 02, 2018 · Filed May 04, 2018
Section 16 reporting ended · disclosed 2018-05-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $0.98 · Expires 2023-05-02 | Direct | 100,000 |
Reported balance
After 2018-05-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-05-02 · Grant · Acquired 100,000 · Balance 100,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2026 Filed Jun 18, 2026 23:24 UTC | Fabric.AI, Inc. FABC · Entity 7732 | GrantEmployee Stock Option (Right to Buy · Derivative | 50,000 | $0.00 Strike: $3.70 | $0.00 |
DisclosureSEC source: 0001493152-26-029427 · ownership.xml · derivative · entry 1 Ramelli Joseph W. · CIK 0001559647 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2036-06-18 F1 · derivative.exercise_date: The stock options vest as follows: (i) 25% vested upon the date of grant; (ii) 25% will vest on June 30, 2026, (iii) 25% will vest on September 30, 2026, and (iv) 25% will vest on December 31, 2026, provided that the Reporting Person remains employed by or providing services to the Issuer on the applicable vesting date. Read SEC document |
| April 30, 2025 Filed May 7, 2025 22:11 UTC | Fabric.AI, Inc. AYRO · Entity 7732 | GrantEmployee Stock Option (Right to Buy · Derivative | 75,000 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0001641172-25-009100 · ownership.xml · derivative · entry 1 Ramelli Joseph W. · CIK 0001559647 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2035-04-30 F1 · derivative.exercise_date: The stock options vested fully on the date of grant. Read SEC document |
| May 02, 2018 Filed May 4, 2018 17:00 UTC | Adhera Therapeutics, Inc. MRNA · Entity 127789 | GrantOptions to purchase common stock · Derivative | 100,000 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001493152-18-006282 · form4.xml · derivative · entry 1 Ramelli Joseph W. · CIK 0001559647 · Former Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: common stock · 100,000 shares Expires 2023-05-02 Read SEC document |
| April 07, 2017 Filed Apr 7, 2017 12:50 UTC | Adhera Therapeutics, Inc. MRNA · Entity 127789 | PurchaseCommon Stock | 22,500 | $0.43 | $9,562.50 |
DisclosureSEC source: 0001559647-17-000002 · primary_doc.xml · nonDerivative · entry 1 Ramelli Joseph W. · CIK 0001559647 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 440,653 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.38 to $0.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| April 06, 2017 Filed Apr 7, 2017 12:50 UTC | Adhera Therapeutics, Inc. MRNA · Entity 127789 | PurchaseCommon Stock | 13,000 | $0.34 | $4,368.00 |
DisclosureSEC source: 0001559647-17-000002 · primary_doc.xml · nonDerivative · entry 2 Ramelli Joseph W. · CIK 0001559647 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 418,153 F2 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.335 to $0.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (2) to this Form 4. Read SEC document |
| April 05, 2017 Filed Apr 5, 2017 17:41 UTC | Adhera Therapeutics, Inc. MRNA · Entity 127789 | PurchaseCommon Stock | 97,550 | $0.31 | $30,435.60 |
DisclosureSEC source: 0001559647-17-000001 · primary_doc.xml · nonDerivative · entry 1 Ramelli Joseph W. · CIK 0001559647 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405,153 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.29 to $0.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| February 02, 2017 Filed Feb 3, 2017 12:46 UTC | Adhera Therapeutics, Inc. MRNA · Entity 127789 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-17-001082 · form4.xml · nonDerivative · entry 1 Ramelli Joseph W. · CIK 0001559647 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,603 F1 · shares: Represents restricted shares of common stock awarded to the reporting person on February 2, 2017 pursuant to the employment letter dated February 2, 2017 between the reporting person and the issuer. Such restricted shares shall vest upon the first execution and delivery by the issuer following the date of the employment letter of a definitive agreement involving the licensing by the issuer its Smarticles-based liposomal delivery technology. The restricted shares were issued under the issuer's 2014 Long-Term Incentive Plan. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 18:29 UTC | Adhera Therapeutics, Inc. MRNA · Entity 127789 | GrantOptions to purchase common stock · Derivative | 81,000 | $0.00 Strike: $0.17 | $0.00 |
DisclosureSEC source: 0001493152-17-000150 · form4.xml · derivative · entry 1 Ramelli Joseph W. · CIK 0001559647 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,000 Underlying: common stock · 81,000 shares Expires 2022-01-03 F1 · derivative.exercise_date: Options to purchase 40,500 shares of common stock are exercisable beginning on January 3, 2017, and options to purchase 40,500 shares of common stock are exercisable beginning on January 3, 2018. Read SEC document |
| November 15, 2016 Filed Nov 17, 2016 17:30 UTC | Adhera Therapeutics, Inc. MRNA · Entity 127789 | GrantOptions to purchase common stock · Derivative | 35,000 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001493152-16-015241 · form4.xml · derivative · entry 1 Ramelli Joseph W. · CIK 0001559647 · Director · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common stock · 35,000 shares Expires 2021-11-15 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.